Clinical Utility of Regadenoson for Assessing Fractional Flow Reserve

Nair, Pradeep; Marroquin, Oscar C.; Mulukutla, Suresh; Khandhar, Sameer; Gulati, Vijay K.; Schindler, John; Lee, Joon S.

doi:10.1016/j.jcin.2011.07.011

Cited by 69 publications

(49 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors demonstrated that this upregulated CD73 can be exploited to convert an inactive A 2A receptor agonist precursor into its active anti-inflammatory analog selectively at the site of inflammation, where the CD73/A 2A receptor axis was induced [57]. The advantage of converting this prodrug as a local effect in the joints was the reduction in side effects that are normally present when A 2A agonists are administered systematically [107,108]. …”

Section: Regulation Of Immunity By Cd39 and Cd73 In Autoimmune Diseasesmentioning

confidence: 99%

CD39 and CD73 in immunity and inflammation

Antonioli

Pacher

Vizi

et al. 2013

Trends in Molecular Medicine

1,007

933

View full text Add to dashboard Cite

The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ecto-enzymes are novel therapeutic targets for managing a variety of disorders.

show abstract

Section: Regulation Of Immunity By Cd39 and Cd73 In Autoimmune Diseasesmentioning

confidence: 99%

CD39 and CD73 in immunity and inflammation

Antonioli

Pacher

Vizi

et al. 2013

Trends in Molecular Medicine

1,007

933

View full text Add to dashboard Cite

show abstract

“…If necessary, the pressure wire can be Table 1 and for further discussion refer to the literature. [15][16][17][18] Clinical Applications of FFR Initially, FFR was used to investigate the functional significance of intermediate lesions, 4 over time it has been validated as useful in most clinical and angiographic conditions encountered in the catheterization laboratory. FFR has been well validated in multivessel disease, left main disease, ostial lesions, tandem lesions, diffuse disease, unstable angina pectoris and non-STEMI.…”

Section: Practical Set-up and Recommendationsmentioning

confidence: 99%

Fractional Flow Reserve to Guide Coronary Revascularization

Pijls

2013

Circ J

View full text Add to dashboard Cite

“…15 The estimated SD of the mean FFR value is 0.1 based on previous studies. [16][17][18][19] The sample size, 50, will give a 95% CI of 95% limits of agreement (LOA) about ±0.048, 20 which is sufficiently narrow and appropriate to assess the similarities with adequate accuracy.…”

Section: Sample Size Calculationmentioning

confidence: 99%

Efficacy of intravenous nicorandil for fractional flow reserve assessment: study protocol for a crossover randomised trial

et al. 2016

View full text Add to dashboard Cite

IntroductionNicorandil has vasodilatory effects on both the epicardial coronary arteries and the coronary microvasculature, thereby increasing coronary blood flow. Intravenous administration of nicorandil can be applicable for fractional flow reserve (FFR) measurement as a hyperaemic agent and a possible alternative to adenosine. However, the effectiveness of intravenous nicorandil infusion for FFR measurement is largely unclear.Methods and analysisThis crossover randomised study is being performed to investigate the efficacy of intravenous administration of nicorandil for FFR measurement. Patients with an intermediate coronary artery stenosis who satisfy the eligibility criteria undergo FFR measurement with a consecutive randomised order of patient-blind infusions of continuous intravenous administration of adenosine and a single bolus intravenous administration of nicorandil. The primary end point of the study is the agreement between the FFR values obtained by the intravenous nicorandil and those obtained by the intravenous adenosine. Recruitment of this trial started in November 2015 and will end in March 2017, or until a total of 50 participants have been recruited.Ethics and disseminationThe protocol was approved by the Institutional Review Board at Chiba University Hospital. Study findings will be published in peer-reviewed journals.Trial registration numberUMIN000019309; Pre-results.

show abstract

Clinical Utility of Regadenoson for Assessing Fractional Flow Reserve

Abstract: Our results suggest that a single IV bolus of regadenoson is as effective as an intravenous infusion of adenosine for measuring FFR and, given its ease of use, should be considered for FFR measurement in the catheterization laboratory.

Cited by 69 publications

References 40 publications

CD39 and CD73 in immunity and inflammation

CD39 and CD73 in immunity and inflammation

Fractional Flow Reserve to Guide Coronary Revascularization

Efficacy of intravenous nicorandil for fractional flow reserve assessment: study protocol for a crossover randomised trial

Contact Info

Product

Resources

About